Portfoliotracker

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

002399.SZ · SHENZHEN · Healthcare Drug Manufacturers - Specialty & Generic 56/100 C

9,080 CNY
▼ −0,040 (−0,44 %)
Closed delayed by 15 min
Price as of 17. 11. 08:04, fetched 17. 11. 16:47
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score56 / 100 Market cap13,4 mld. CNY P/E65,8 Forward P/E16,5 P/S2,5 P/B1,1 EV/EBITDA20,2 Dividend yield1,59 % FCF yield10,48 % EPS0,13 CNY Net margin3,7 % Return on equity1,5 % Beta0,31 Debt / equity0,25
52-week range 8,50 to 12,68
3-month average volume5,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Employees
2 150
Country
China
Data since
6. 5. 2010

Explore further

Similar companies 000999.SZ002422.SZ000559.SZ002236.SZ002294.SZ

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account